Press release - 02/02/2012 Colorectal cancer: Phase II results with cancer vaccine IMA910 are positive immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announced positive results from its Phase II clinical trial with IMA910 in patients with advanced colorectal cell carcinoma (CRC) which were presented at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO) in San Francisco. IMA910 comprises 13 tumor-associated…https://www.gesundheitsindustrie-bw.de/en/article/press-release/colorectal-cancer-phase-ii-results-with-cancer-vaccine-ima910-are-positive
Article - 19/12/2011 Gundram Jung – a pioneer in antibody-mediated cancer immunotherapy Physicist, medical doctor, researcher and now also a founder of a company – Professor Dr. Gundram Jung’s career has never gone in a completely straight line although his goal has always been the same: to develop innovative immunotherapies for the treatment of cancer. Jung’s genetically modified antitumour antibodies are now close to clinical application. https://www.gesundheitsindustrie-bw.de/en/article/news/gundram-jung-a-pioneer-in-antibody-mediated-cancer-immunotherapy
Article - 21/11/2011 Johannes Huebner's interest in intestinal bacteria and their sweet-sour capsule Some Enterococcus species are common commensal organisms in human intestines and other species are used in raw-milk cheese where they enhance flavour development. On the negative side enterococci are also a common cause of hospital-acquired infections. Prof. Dr. Johannes Huebner from the Freiburg University Medical Centre is hoping that the bacterias capsular polysaccharides might at some point in the future be used as a vaccine opening the door…https://www.gesundheitsindustrie-bw.de/en/article/news/johannes-huebner-s-interest-in-intestinal-bacteria-and-their-sweet-sour-capsule
Press release - 15/11/2011 Lung cancer: CureVac presents results of a Phase I/IIa trial with an mRNA based vaccine CureVac GmbH, the mRNA vaccine company, presented at the 26th Annual SITC Meeting in Washington the results of a Phase I/IIa trial in non-small cell lung cancer (NSCLC) with CV9201, an mRNA-based cancer vaccine, in patients with NSCLC stage IIIB/IV after first-line chemo-radiotherapy or chemotherapy, respectively.https://www.gesundheitsindustrie-bw.de/en/article/press-release/lung-cancer-curevac-presents-results-of-a-phase-i-iia-trial-with-an-mrna-based-vaccine
Press release - 15/11/2011 CureVac, Sanofi Pasteur and In-Cell-Art collaborate on a $33.1 million project CureVac GmbH today announced the signing of several agreements with Sanofi Pasteur S.A., the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY). Under these agreements, CureVac and Sanofi Pasteur will further develop and apply CureVac’s proprietary RNActive® technology platform to the development of vaccines against several infectious diseases.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-sanofi-pasteur-and-in-cell-art-collaborate-on-a-33-1-million-project
Article - 17/10/2011 Papillomaviruses as cancer-causing agents and how they can be fought off Studies presented at the recent International Papillomavirus Conference in Berlin demonstrate that vaccination can prevent infection with the types of HPV that cause the majority of cervical cancers. New improved vaccines to prevent HPV infections as well as therapeutic vaccines that are effective in people that are already infected are currently being developed. In addition, research has shown that other cancers can also be caused by infective…https://www.gesundheitsindustrie-bw.de/en/article/news/papillomaviruses-as-cancer-causing-agents-and-how-they-can-be-fought-off
Article - 12/09/2011 TransLimm brings new immunotherapies to patients more rapidly With the establishment of the Center for Translational Immunology TransLimm the University of Tübingen has initiated a network whose objective is to quickly and effectively transfer innovative therapies into clinical application. Patients suffering from acute leukaemia might soon benefit from therapies involving antibodies optimized by recombinant antibody technology. https://www.gesundheitsindustrie-bw.de/en/article/news/translimm-brings-new-immunotherapies-to-patients-more-rapidly
Article - 29/07/2011 Labor Dr. Merk und Kollegen - Viruses under control It is difficult to imagine how Ochsenhausen-based Labor Dr. Merk und Kollegen (LMK) would be able to develop, produce and test medical products for bacterial and viral contaminations without using cell cultures. The medium-sized company also produces viruses for testing and has stored more than 80 different viruses – enveloped and non-enveloped ones, animal and human pathogens – at -80˚C.https://www.gesundheitsindustrie-bw.de/en/article/news/labor-dr-merk-und-kollegen-viruses-under-control
Press release - 20/06/2011 CureVac presents new data for prostate and lung cancer vaccines CureVac GmbH presented promising new data for prostate cancer vaccine CV9103 and lung cancer vaccine CV9201 at the ASCO Conference in Chicago. Final trial results confirm safety and excellent antigen-specific immunogenicity of prostate cancer vaccine CV9103. And initial promising data from phase I/IIa trial of lung cancer vaccine CV9201 further supports the potential of CureVac’s RNActive® vaccination technology in cancer immunotherapy and…https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-presents-new-data-for-prostate-and-lung-cancer-vaccines
Press release - 15/06/2011 immatics’ pivotal Phase III trial with IMA901: First patients with renal cell carcinoma are vaccinated immatics biotechnologies GmbH, a biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announced today that the first patients have been vaccinated in the IMPRINT study, a pivotal Phase III trial with IMA901, the company’s lead cancer vaccine for the treatment of renal cell carcinoma (RCC).https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-pivotal-phase-iii-trial-with-ima901-first-patients-with-renal-cell-carcinoma-are-vaccinated
Press release - 02/03/2011 immatics appoints Dr. Harald Stock to its Board immatics biotechnologies GmbH, a late-stage biopharmaceutical company developing therapeutic vaccines that are active against cancer, today announced the appointment of Dr. Harald F. Stock to the board of directors, effective February 2011.https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-appoints-dr-harald-stock-to-its-board
Article - 28/02/2011 Development of food allergies Allergic reactions to certain types of food can, in extreme cases, lead to life-threatening anaphylactic shock. People with peanut allergies are particularly at risk. Allergic reactions can also gradually develop into chronic intolerances such as coeliac disease, for example. The causes of food allergies nearly always originate in early childhood. https://www.gesundheitsindustrie-bw.de/en/article/news/development-of-food-allergies
Dossier - 28/02/2011 Allergies – a major human plague According to the Federal Health Monitoring Information System a persons life expectancy is reduced by around one per cent due to allergies and their effects. Knowledge about the molecular mechanisms that lead to disorders in the interplay of the immune system and the environment is a prerequisite for developing new therapies for the causal treatment of allergies.https://www.gesundheitsindustrie-bw.de/en/article/dossier/allergies-a-major-human-plague
Article - 14/02/2011 Marilena Manea: targeted chemotherapy to treat cancer After cardiovascular diseases cancer is the second leading cause of death in Germany. At the University of Konstanz Dr. Marilena Manea and her research group are working on the development of bioconjugates for targeted cancer chemotherapy. The researchers goal is to improve the efficiency and tolerability of the chemotherapeutic drugs that are already being used in hospitals.https://www.gesundheitsindustrie-bw.de/en/article/news/marilena-manea-targeted-chemotherapy-to-treat-cancer
Article - 10/01/2011 Review: What does the cell factory of the future look like? A symposium on “Cell Factories of the Future” was held at the Laupheim-based company Rentschler Biotechnologie on 14th and 15th October 2010. The event attracted around 70 scientists from academia and industry and will now take place every two years. The symposium focused on new biomanufacturing developments and technologies, and included lectures on (animal) cells, cell factories and the future of recombinant protein production. https://www.gesundheitsindustrie-bw.de/en/article/news/review-what-does-the-cell-factory-of-the-future-look-like
Article - 03/12/2010 Review: Science meets Business Day 2010 (part II) How can plant physiologists and seed developers work together to achieve an understanding of the processes happening in the germinating plant embryo in order to improve the seed quality of sugar beet? How can virologists find new ways to switch off the flu virus and develop a marketable vaccine in cooperation with industrial partners?https://www.gesundheitsindustrie-bw.de/en/article/news/review-science-meets-business-day-2010-part-ii
Article - 29/11/2010 Against chronic liver inflammation and liver cancer Chronic hepatitis B and C are the major causes of liver cancer. In contrast to hepatitis B viruses, there is no hepatitis C virus vaccination available. New research carried out by Professor Bartenschlager and his colleagues from Heidelberg might give rise to new strategies for the development of vaccines and medications for the prevention and treatment of chronic hepatitis C virus infections.https://www.gesundheitsindustrie-bw.de/en/article/news/against-chronic-liver-inflammation-and-liver-cancer
Dossier - 29/11/2010 Drug safety and the difficulty of making ends meet Everybody wants safe drugs – manufacturers, doctors and patients. However, many dangers, both avoidable and unavoidable, make medicinal treatment a high-risk process, despite all best efforts and assertions. Not enough information on drug-related risks is available, and the estimated number of adverse drug reactions that go unreported is quite high.https://www.gesundheitsindustrie-bw.de/en/article/dossier/drug-safety-and-the-difficulty-of-making-ends-meet
Press release - 21/09/2010 immatics raises 54 million euros to advance its late stage clinical therapeutic cancer vaccine portfolio immatics biotechnologies GmbH a biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer announced today that it has raised 53.8million in a Series C financing round. The new funds will allow the Company to finance the ongoing development of immatics existing pipeline of advanced therapeutic cancer vaccine candidates. https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-raises-54-million-euros-to-advance-its-late-stage-clinical-therapeutic-cancer-vaccine-portf
Press release - 09/09/2010 China Medical City, Taizhou Taizhou is a commercial and industrial city of around 5 million inhabitants located in the Yantze River Delta about half way between Nanjing and Suzhou. Within the Taizhou city boundaries on a total area of 25 square kilometers China Medical City CMC a national-level pharmaceutical high-tech park is currently under construction. https://www.gesundheitsindustrie-bw.de/en/article/press-release/china-medical-city-taizhou
Press release - 08/09/2010 Prevention and Treatment of Chronic Hepatitis C GENOVAC and Inserm co-develop a novel antibody-based approach for prevention and treatment of chronic hepatitis C.https://www.gesundheitsindustrie-bw.de/en/article/press-release/prevention-and-treatment-of-chronic-hepatitis-c
Article - 30/08/2010 Diagnostics for the early detection of cervical cancer The Pap test is regarded as the most successful test for cancer ever, and has saved the lives of many women. However, the test is associated with several weaknesses. The Heidelberg-based in vitro diagnostics company mtm laboratories AG develops and commercialises highly sensitive and highly specific immunochemical tests that provide greater reliability. These tests have the potential to revolutionise the early detection of cervical cancer.https://www.gesundheitsindustrie-bw.de/en/article/news/diagnostics-for-the-early-detection-of-cervical-cancer
Article - 23/08/2010 Antibiotics for the prevention of malaria Researchers from Heidelberg and Berlin have shown that if malaria-infected mice are administered an antibiotic, no parasites appear in the blood and the mice are protected from this life-threatening disease. The scientists believe that antibiotics also have the potential to strengthen the human immune system as well as making it possible to provide a natural needle-free vaccination against malaria.https://www.gesundheitsindustrie-bw.de/en/article/news/antibiotics-for-the-prevention-of-malaria
Press release - 02/08/2010 GMP Centre established in Tübingen The Good Manufacturing Practice Zentrum GMP-Zentrum GMP Centre of Tübingen University Hospital was officially opened on 16th July. The GMP-Zentrum was established to enable the production of individualised vaccines and antibodies according to the rules of good pharmaceutical practice for the treatment of cancer patients.https://www.gesundheitsindustrie-bw.de/en/article/press-release/gmp-centre-established-in-tuebingen
Press release - 21/07/2010 One Million for Cancer Research from Manfred Lautenschläger Foundation When Harald zur Hausen was awarded the Nobel Prize for Medicine in 2008, Manfred Lautenschläger spontaneously offered to support the Nobel laureate’s scientific work by funding a new research team. These funds will now go to Angelika Riemer, a young scientist who plans to advance the development of a vaccine which is able to cure existing infections with carcinogenic human papillomaviruses at the German Cancer Research Center (Deutsches…https://www.gesundheitsindustrie-bw.de/en/article/press-release/one-million-for-cancer-research-from-manfred-lautenschlaeger-foundation